메뉴 건너뛰기




Volumn 71, Issue , 2014, Pages 62-73

Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging

Author keywords

Aging; D1994S knock in; G2019S knock in; H 1152; LRRK2; LRRK2 kinase inhibitors; LRRK2 kinase dead; Nov LRRK2 11; Parkinson's disease; Ser935 phosphorylation

Indexed keywords

ENZYME INHIBITOR; GLYCINE; H 1152; LEUCINE RICH REPEAT KINASE 2; LEUCINE RICH REPEAT KINASE 2 11; PROTEIN KINASE INHIBITOR; SERINE; UNCLASSIFIED DRUG; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2-METHYL-1-((4-METHYL-5-ISOQUINOLINYL)SULFONYL)HOMOPIPERAZINE; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

EID: 84906572600     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.07.013     Document Type: Article
Times cited : (44)

References (66)
  • 1
    • 48349136889 scopus 로고    scopus 로고
    • Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
    • Barrett J.C., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 2008, 40:955-962.
    • (2008) Nat. Genet. , vol.40 , pp. 955-962
    • Barrett, J.C.1
  • 2
    • 84866065925 scopus 로고    scopus 로고
    • (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD
    • Chen C.Y., et al. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ. 2012, 19:1623-1633.
    • (2012) Cell Death Differ. , vol.19 , pp. 1623-1633
    • Chen, C.Y.1
  • 3
    • 84865032690 scopus 로고    scopus 로고
    • Brain penetrant LRRK2 inhibitor
    • Choi H.G., et al. Brain penetrant LRRK2 inhibitor. ACS Med. Chem. Lett. 2012, 3:658-662.
    • (2012) ACS Med. Chem. Lett. , vol.3 , pp. 658-662
    • Choi, H.G.1
  • 4
    • 84901669528 scopus 로고    scopus 로고
    • LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex
    • Cirnaru M.D., et al. LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Front. Mol. Neurosci. 2014, 7:49.
    • (2014) Front. Mol. Neurosci. , vol.7 , pp. 49
    • Cirnaru, M.D.1
  • 5
    • 78649389313 scopus 로고    scopus 로고
    • The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
    • Cookson M.R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci. 2010, 11:791-797.
    • (2010) Nat. Rev. Neurosci. , vol.11 , pp. 791-797
    • Cookson, M.R.1
  • 6
    • 77956655427 scopus 로고    scopus 로고
    • Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization
    • Dzamko N., et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J. 2010, 430:405-413.
    • (2010) Biochem. J. , vol.430 , pp. 405-413
    • Dzamko, N.1
  • 7
    • 84862497413 scopus 로고    scopus 로고
    • The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling
    • Dzamko N., et al. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 2012, 7:e39132.
    • (2012) PLoS One , vol.7
    • Dzamko, N.1
  • 8
    • 84870051317 scopus 로고    scopus 로고
    • Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors
    • Estrada A.A., et al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem. 2012, 55:9416-9433.
    • (2012) J. Med. Chem. , vol.55 , pp. 9416-9433
    • Estrada, A.A.1
  • 9
    • 84894097684 scopus 로고    scopus 로고
    • Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors
    • Estrada A.A., et al. Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem. 2014, 57:921-936.
    • (2014) J. Med. Chem. , vol.57 , pp. 921-936
    • Estrada, A.A.1
  • 10
    • 84862996255 scopus 로고    scopus 로고
    • Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations
    • Gilsbach B.K., et al. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:10322-10327.
    • (2012) Proc. Natl. Acad. Sci. U. S. A. , vol.109 , pp. 10322-10327
    • Gilsbach, B.K.1
  • 11
    • 33746267531 scopus 로고    scopus 로고
    • Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
    • Greggio E., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
    • (2006) Neurobiol. Dis. , vol.23 , pp. 329-341
    • Greggio, E.1
  • 12
    • 78651440972 scopus 로고    scopus 로고
    • Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
    • Greggio E., et al. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?. Mol. Neurodegener. 2011, 6:6.
    • (2011) Mol. Neurodegener. , vol.6 , pp. 6
    • Greggio, E.1
  • 13
    • 68649097307 scopus 로고    scopus 로고
    • The genetics of Parkinson's syndromes: a critical review
    • Hardy J., et al. The genetics of Parkinson's syndromes: a critical review. Curr. Opin. Genet. Dev. 2009, 19:254-265.
    • (2009) Curr. Opin. Genet. Dev. , vol.19 , pp. 254-265
    • Hardy, J.1
  • 14
    • 65449160605 scopus 로고    scopus 로고
    • The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel
    • Hassin-Baer S., et al. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J. Neurol. 2009, 256:483-487.
    • (2009) J. Neurol. , vol.256 , pp. 483-487
    • Hassin-Baer, S.1
  • 15
    • 50049104725 scopus 로고    scopus 로고
    • Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
    • Healy D.G., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
    • (2008) Lancet Neurol. , vol.7 , pp. 583-590
    • Healy, D.G.1
  • 16
    • 84885452439 scopus 로고    scopus 로고
    • Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease
    • Hennis M.R., et al. Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease. Neurobiol. Dis. 2014, 62:113-123.
    • (2014) Neurobiol. Dis. , vol.62 , pp. 113-123
    • Hennis, M.R.1
  • 17
    • 80053968304 scopus 로고    scopus 로고
    • LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice
    • Herzig M.C., et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 2011, 20:4209-4223.
    • (2011) Hum. Mol. Genet. , vol.20 , pp. 4209-4223
    • Herzig, M.C.1
  • 18
    • 84866145895 scopus 로고    scopus 로고
    • High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain
    • Herzig M.C., et al. High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One 2012, 7:e36581.
    • (2012) PLoS One , vol.7
    • Herzig, M.C.1
  • 19
    • 33845796537 scopus 로고    scopus 로고
    • Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain
    • Higashi S., et al. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 2007, 100:368-381.
    • (2007) J. Neurochem. , vol.100 , pp. 368-381
    • Higashi, S.1
  • 20
    • 84861552733 scopus 로고    scopus 로고
    • LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors
    • Hinkle K.M., et al. LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol. Neurodegener. 2012, 7:25.
    • (2012) Mol. Neurodegener. , vol.7 , pp. 25
    • Hinkle, K.M.1
  • 21
    • 34447294546 scopus 로고    scopus 로고
    • Apoptotic mechanisms in mutant LRRK2-mediated cell death
    • Iaccarino C., et al. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 2007, 16:1319-1326.
    • (2007) Hum. Mol. Genet. , vol.16 , pp. 1319-1326
    • Iaccarino, C.1
  • 22
    • 34447118788 scopus 로고    scopus 로고
    • LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity
    • Jaleel M., et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007, 405:307-317.
    • (2007) Biochem. J. , vol.405 , pp. 307-317
    • Jaleel, M.1
  • 23
    • 0032143368 scopus 로고    scopus 로고
    • Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat
    • Kirik D., et al. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 1998, 152:259-277.
    • (1998) Exp. Neurol. , vol.152 , pp. 259-277
    • Kirik, D.1
  • 24
    • 84879221281 scopus 로고    scopus 로고
    • Genome-wide association study signal at the 12q12 locus for Crohn's disease may represent associations with the MUC19 gene
    • Kumar V., et al. Genome-wide association study signal at the 12q12 locus for Crohn's disease may represent associations with the MUC19 gene. Inflamm. Bowel Dis. 2013, 19:1254-1259.
    • (2013) Inflamm. Bowel Dis. , vol.19 , pp. 1254-1259
    • Kumar, V.1
  • 25
    • 0015372223 scopus 로고
    • Morphine catalepsy in the rat: relation to striatal dopamine metabolism
    • Kuschinsky K., Hornykiewicz O. Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur. J. Pharmacol. 1972, 19:119-122.
    • (1972) Eur. J. Pharmacol. , vol.19 , pp. 119-122
    • Kuschinsky, K.1    Hornykiewicz, O.2
  • 26
    • 79955629341 scopus 로고    scopus 로고
    • Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein
    • Lam H.A., et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J. Neurosci. Res. 2011, 89:1091-1102.
    • (2011) J. Neurosci. Res. , vol.89 , pp. 1091-1102
    • Lam, H.A.1
  • 27
    • 77956441086 scopus 로고    scopus 로고
    • Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
    • Lee B.D., et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. 2010, 16:998-1000.
    • (2010) Nat. Med. , vol.16 , pp. 998-1000
    • Lee, B.D.1
  • 28
    • 76149134717 scopus 로고    scopus 로고
    • Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S
    • Li X., et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 2010, 30:1788-1797.
    • (2010) J. Neurosci. , vol.30 , pp. 1788-1797
    • Li, X.1
  • 29
    • 79952302007 scopus 로고    scopus 로고
    • Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease
    • Li X., et al. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 2011, 6:e17153.
    • (2011) PLoS One , vol.6
    • Li, X.1
  • 30
    • 72149087091 scopus 로고    scopus 로고
    • Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein
    • Lin X., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
    • (2009) Neuron , vol.64 , pp. 807-827
    • Lin, X.1
  • 31
    • 80053152848 scopus 로고    scopus 로고
    • Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models
    • Liu Z., et al. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum. Mol. Genet. 2011, 20:3933-3942.
    • (2011) Hum. Mol. Genet. , vol.20 , pp. 3933-3942
    • Liu, Z.1
  • 32
    • 33750931271 scopus 로고    scopus 로고
    • The Parkinson disease gene LRRK2: evolutionary and structural insights
    • Marin I. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol. Biol. Evol. 2006, 23:2423-2433.
    • (2006) Mol. Biol. Evol. , vol.23 , pp. 2423-2433
    • Marin, I.1
  • 33
    • 3342929522 scopus 로고    scopus 로고
    • Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior
    • Marti M., et al. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J. Neurosci. 2004, 24:6659-6666.
    • (2004) J. Neurosci. , vol.24 , pp. 6659-6666
    • Marti, M.1
  • 34
    • 27144554951 scopus 로고    scopus 로고
    • Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease
    • Marti M., et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J. Neurosci. 2005, 25:9591-9601.
    • (2005) J. Neurosci. , vol.25 , pp. 9591-9601
    • Marti, M.1
  • 35
    • 33847003007 scopus 로고    scopus 로고
    • The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway
    • Marti M., et al. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J. Neurosci. 2007, 27:1297-1307.
    • (2007) J. Neurosci. , vol.27 , pp. 1297-1307
    • Marti, M.1
  • 36
    • 33646151866 scopus 로고    scopus 로고
    • LRRK2 in Parkinson's disease: protein domains and functional insights
    • Mata I.F., et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006, 29:286-293.
    • (2006) Trends Neurosci. , vol.29 , pp. 286-293
    • Mata, I.F.1
  • 37
    • 84866510734 scopus 로고    scopus 로고
    • LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis
    • Matta S., et al. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 2012, 75:1008-1021.
    • (2012) Neuron , vol.75 , pp. 1008-1021
    • Matta, S.1
  • 38
    • 34547107314 scopus 로고    scopus 로고
    • A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease
    • Melrose H.L., et al. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007, 147:1047-1058.
    • (2007) Neuroscience , vol.147 , pp. 1047-1058
    • Melrose, H.L.1
  • 39
    • 77957794336 scopus 로고    scopus 로고
    • Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice
    • Melrose H.L., et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 2010, 40:503-517.
    • (2010) Neurobiol. Dis. , vol.40 , pp. 503-517
    • Melrose, H.L.1
  • 40
    • 84885989906 scopus 로고    scopus 로고
    • LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization
    • Migheli R., et al. LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. PLoS One 2013, 8:e77198.
    • (2013) PLoS One , vol.8
    • Migheli, R.1
  • 41
    • 84891904255 scopus 로고    scopus 로고
    • Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3
    • Muda K., et al. Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E34-E43.
    • (2014) Proc. Natl. Acad. Sci. U. S. A. , vol.111
    • Muda, K.1
  • 42
    • 70350653779 scopus 로고    scopus 로고
    • Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
    • Nichols R.J., et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem. J. 2009, 424:47-60.
    • (2009) Biochem. J. , vol.424 , pp. 47-60
    • Nichols, R.J.1
  • 43
    • 8844266996 scopus 로고    scopus 로고
    • Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
    • Paisan-Ruiz C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
    • (2004) Neuron , vol.44 , pp. 595-600
    • Paisan-Ruiz, C.1
  • 44
    • 84896736721 scopus 로고    scopus 로고
    • LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity
    • Parisiadou L., et al. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat. Neurosci. 2014, 17:367-376.
    • (2014) Nat. Neurosci. , vol.17 , pp. 367-376
    • Parisiadou, L.1
  • 45
    • 79951534656 scopus 로고    scopus 로고
    • LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool
    • Piccoli G., et al. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci. 2011, 31:2225-2237.
    • (2011) J. Neurosci. , vol.31 , pp. 2225-2237
    • Piccoli, G.1
  • 46
    • 79953758383 scopus 로고    scopus 로고
    • Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2
    • Ramonet D., et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011, 6:e18568.
    • (2011) PLoS One , vol.6
    • Ramonet, D.1
  • 47
    • 43449090397 scopus 로고    scopus 로고
    • Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice
    • Rizzi A., et al. Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br. J. Pharmacol. 2008, 154:471-479.
    • (2008) Br. J. Pharmacol. , vol.154 , pp. 471-479
    • Rizzi, A.1
  • 48
    • 0031402010 scopus 로고    scopus 로고
    • An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism
    • Rozas G., et al. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res. Brain Res. Protocol. 1997, 2:75-84.
    • (1997) Brain Res. Brain Res. Protocol. , vol.2 , pp. 75-84
    • Rozas, G.1
  • 49
    • 0023680943 scopus 로고
    • The catalepsy test: its ups and downs
    • Sanberg P.R., et al. The catalepsy test: its ups and downs. Behav. Neurosci. 1988, 102:748-759.
    • (1988) Behav. Neurosci. , vol.102 , pp. 748-759
    • Sanberg, P.R.1
  • 50
    • 0035990918 scopus 로고    scopus 로고
    • The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway
    • Sasaki Y., et al. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 2002, 93:225-232.
    • (2002) Pharmacol. Ther. , vol.93 , pp. 225-232
    • Sasaki, Y.1
  • 51
    • 0018421663 scopus 로고
    • Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism
    • Schallert T., et al. Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Exp. Neurol. 1979, 64:33-43.
    • (1979) Exp. Neurol. , vol.64 , pp. 33-43
    • Schallert, T.1
  • 52
    • 84874720265 scopus 로고    scopus 로고
    • Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations
    • 164ra161
    • Sheng Z., et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 2012, 4:164ra161.
    • (2012) Sci. Transl. Med. , vol.4
    • Sheng, Z.1
  • 53
    • 84891776413 scopus 로고    scopus 로고
    • Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies
    • Skibinski G., et al. Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J. Neurosci. 2014, 34:418-433.
    • (2014) J. Neurosci. , vol.34 , pp. 418-433
    • Skibinski, G.1
  • 54
    • 29444437871 scopus 로고    scopus 로고
    • Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration
    • Smith W.W., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18676-18681.
    • (2005) Proc. Natl. Acad. Sci. U. S. A. , vol.102 , pp. 18676-18681
    • Smith, W.W.1
  • 55
    • 78650209340 scopus 로고    scopus 로고
    • Dopamine turnover increases in asymptomatic LRRK2 mutations carriers
    • Sossi V., et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov. Disord. 2010, 25:2717-2723.
    • (2010) Mov. Disord. , vol.25 , pp. 2717-2723
    • Sossi, V.1
  • 56
    • 29144527049 scopus 로고    scopus 로고
    • Development of specific Rho-kinase inhibitors and their clinical application
    • Tamura M., et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim. Biophys. Acta 2005, 1754:245-252.
    • (2005) Biochim. Biophys. Acta , vol.1754 , pp. 245-252
    • Tamura, M.1
  • 57
    • 77649105209 scopus 로고    scopus 로고
    • Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau
    • Taymans J.M., Cookson M.R. Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 2010, 32:227-235.
    • (2010) Bioessays , vol.32 , pp. 227-235
    • Taymans, J.M.1    Cookson, M.R.2
  • 58
    • 70149124508 scopus 로고    scopus 로고
    • R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice
    • Tong Y., et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14622-14627.
    • (2009) Proc. Natl. Acad. Sci. U. S. A. , vol.106 , pp. 14622-14627
    • Tong, Y.1
  • 59
    • 84879419522 scopus 로고    scopus 로고
    • Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2
    • Troxler T., et al. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2. Bioorg. Med. Chem. Lett. 2013, 23:4085-4090.
    • (2013) Bioorg. Med. Chem. Lett. , vol.23 , pp. 4085-4090
    • Troxler, T.1
  • 60
    • 43649104203 scopus 로고    scopus 로고
    • Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism
    • Viaro R., et al. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol. Dis. 2008, 30:430-438.
    • (2008) Neurobiol. Dis. , vol.30 , pp. 430-438
    • Viaro, R.1
  • 61
    • 28044460070 scopus 로고    scopus 로고
    • Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
    • West A.B., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16842-16847.
    • (2005) Proc. Natl. Acad. Sci. U. S. A. , vol.102 , pp. 16842-16847
    • West, A.B.1
  • 62
    • 84866657903 scopus 로고    scopus 로고
    • LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease
    • Xiong Y., et al. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. Biochem. Soc. Trans. 2012, 40:1074-1079.
    • (2012) Biochem. Soc. Trans. , vol.40 , pp. 1074-1079
    • Xiong, Y.1
  • 63
    • 79960587095 scopus 로고    scopus 로고
    • Genetic LRRK2 models of Parkinson's disease: dissecting the pathogenic pathway and exploring clinical applications
    • Yue Z., Lachenmayer M.L. Genetic LRRK2 models of Parkinson's disease: dissecting the pathogenic pathway and exploring clinical applications. Mov. Disord. 2011, 26:1386-1397.
    • (2011) Mov. Disord. , vol.26 , pp. 1386-1397
    • Yue, Z.1    Lachenmayer, M.L.2
  • 64
    • 74049127960 scopus 로고    scopus 로고
    • Genomewide association study of leprosy
    • Zhang F.R., et al. Genomewide association study of leprosy. N. Engl. J. Med. 2009, 361:2609-2618.
    • (2009) N. Engl. J. Med. , vol.361 , pp. 2609-2618
    • Zhang, F.R.1
  • 65
    • 79960972765 scopus 로고    scopus 로고
    • Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake
    • Zhou H., et al. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int. J. Biol. Sci. 2011, 7:753-761.
    • (2011) Int. J. Biol. Sci. , vol.7 , pp. 753-761
    • Zhou, H.1
  • 66
    • 8844233579 scopus 로고    scopus 로고
    • Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology
    • Zimprich A., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
    • (2004) Neuron , vol.44 , pp. 601-607
    • Zimprich, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.